Agreement - November 8, 2021
SAGA Diagnostics and AstraZeneca enter agreement
SAGA Diagnostics has entered into an assay development agreement with AstraZeneca. SAGA Diagnostics will in the course of this agreement develop SAGAsafe dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies. “We have chosen to partner with SAGA because of the ultrasensitive performance of the SAGAsafe technology and possibility to […]
Financing - June 29, 2021
SAGA Diagnostics raises 106 million SEK
SAGA Diagnostics has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures. “We are delighted to complete this oversubscribed financing round with […]
Collaboration - June 21, 2021
SAGA Diagnostics expands research collaboration
The company has announced an expanded research collaboration with Professor Charles Swanton, at the University College London (UCL) Cancer Institute. Last year, SAGA and UCL entered into a research collaboration on a limited number of patients. With the newly signed agreement, SAGA will utilize its SAGAsafe assays for detection of a panel of mutations in […]
Pharma Diagnostics - June 16, 2021
SAGA Diagnostics achieves ISO 17025 accreditation
SAGA Diagnostics has been accredited to the ISO 17025 standard for its mutation detection laboratory services designed to improve cancer diagnosis, monitoring, and treatment outcomes. Granted by SWEDAC, the Swedish Board for Accreditation and Conformity Assessment, ISO 17025 is an international quality management standard used to assess the competency of analytical laboratories. A milestone “The […]
Agreement - January 29, 2020
SAGA Diagnostics extends collaboration with Servier
SAGA Diagnostics has entered service agreements with the international pharmaceutical company Servier, based in Paris, France. “These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects,” says […]
Careers article - November 14, 2017
Careers interview: Lao Saal, CEO, SAGA Diagnostics
Surviving an episode of cancer as a teenager set Lao Saal on a path to seek out better ways to detect, monitor and treat the deadly cells. That determination drove him to earn medical and doctoral degrees at Columbia University College of Physicians and Surgeons in New York City in 2008, and in 2016, start SAGA Diagnostics AB, in Lund, Sweden. Serving biopharmaceutical companies as well as healthcare and researchers, SAGA applies ultrasensitive technologies […]
